Validation of drug‐resistant epilepsy identification algorithms in US Veterans across diverse care settings

OBJECTIVE: Early recognition of drug-resistant epilepsy (DRE) is critical for timely referral to comprehensive epilepsy centers (CECs). Our prior pilot study in the Veterans Health Administration (VHA) demonstrated the feasibility of an algorithm-based approach to identify DRE within selected CECs. In this study, we validated and refined these algorithms in a broader, national cohort, including CEC and non-CEC care, to optimize algorithms for different care settings. METHODS: We conducted a multicenter, retrospective study of randomly sampled veterans with epilepsy on ≥2 antiseizure medications (ASMs) from 1999 to 2024. Chart review by 26 epilepsy providers rated DRE status. Ninety-six candidate algorithms using combinations of six criteria-number of ASMs, treatment duration, dose thresholds, pregabalin exclusion, intractable International Classification of Diseases (ICD) codes, and electroencephalography (EEG)/magnetic resonance imaging (MRI) utilization-were evaluated. Performance for DRE classification was evaluated among all veterans, and separately for CEC or non-CEC care. RESULTS: Among 970 veterans on ≥2 lifetime ASMs, 518 (53.4%) were rated as DRE, 363 (37.4%) as non-DRE, and 89 (9.2%) as undetermined. Veterans with DRE were younger (mean age = 68.9 vs. 72.0 years) and more frequently had at least one intractable ICD code (46.1% vs. 18.2%), EEG (77.8% vs. 66.7%), or MRI (78.0% vs. 65.8%) compared with non-DRE (all p-values <.001). Among all veterans, the best overall algorithm (area under the curve [AUC] = .701) identified DRE as either (1) exposure to 3+ ASMs or (2) exposure to two ASMs for at least 1 year, with the requirement of past EEG/MRI and intractable ICD code documentation. This algorithm was also highly effective among veterans who received CEC (AUC = .756) or only non-CEC care (AUC = .678). SIGNIFICANCE: This national validation study confirms that medication-based algorithms can identify DRE within VHA administrative data across care settings (CECs and non-CECs). This supports the implementation of a standardized DRE definition for quality improvement, surveillance, and referral optimization within the VHA.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-11-18
DOI
https://doi.org/10.1002/epi.70580
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Validation of drug‐resistant epilepsy identification algorithms in US Veterans across diverse care settings

Elizabeth J. Waterhouse, Rizwana Rehman, Omar I. Khan, Chloé E. Hill et al.
3 links
Epilepsia
Epilepsy research and treatment
article

Validation of drug‐resistant epilepsy identification algorithms in US Veterans across diverse care settings

Elizabeth J. Waterhouse, Rizwana Rehman, Omar I. Khan, Chloé E. Hill, Sarah R. Durica, Christopher S. Zimmerman, Anthony N. Mefford, Richard Zhou, Aditi Narechania, Noemi Rincon‐Flores, Marissa A. Kellogg, Steven D. Tobochnik, Manuel Melo Bicchi, Karen Medin, Jacob Pellinen, Maria Lopez, Jacqueline Hirschey, Daniel Birnbaum, Hina Dave, Mary Jo Pugh, Marcella A Coutts, Andrea D. Hildebrand, Tyler E. Gaston, Zehra Husain, Swapna Surabhi, Kamakshi Patel, Alan R. Towne, Denise Sebasigari, Zulfi Haneef, Melissa Fadipe, Sruthi Gopinath Karicheri, Gina Kayal, Christine Smith, Stephan J. Eisenschenk, Stephanie Reeder, Rohan Sri Nagabhirava, Alexandra Roach, Tung Tran, Rebekah Kaska, Kenichiro Ono, Francisca Ahn
article en

Abstract

OBJECTIVE: Early recognition of drug-resistant epilepsy (DRE) is critical for timely referral to comprehensive epilepsy centers (CECs). Our prior pilot study in the Veterans Health Administration (VHA) demonstrated the feasibility of an algorithm-based approach to identify DRE within selected CECs. In this study, we validated and refined these algorithms in a broader, national cohort, including CEC and non-CEC care, to optimize algorithms for different care settings. METHODS: We conducted a multicenter, retrospective study of randomly sampled veterans with epilepsy on ≥2 antiseizure medications (ASMs) from 1999 to 2024. Chart review by 26 epilepsy providers rated DRE status. Ninety-six candidate algorithms using combinations of six criteria-number of ASMs, treatment duration, dose thresholds, pregabalin exclusion, intractable International Classification of Diseases (ICD) codes, and electroencephalography (EEG)/magnetic resonance imaging (MRI) utilization-were evaluated. Performance for DRE classification was evaluated among all veterans, and separately for CEC or non-CEC care. RESULTS: Among 970 veterans on ≥2 lifetime ASMs, 518 (53.4%) were rated as DRE, 363 (37.4%) as non-DRE, and 89 (9.2%) as undetermined. Veterans with DRE were younger (mean age = 68.9 vs. 72.0 years) and more frequently had at least one intractable ICD code (46.1% vs. 18.2%), EEG (77.8% vs. 66.7%), or MRI (78.0% vs. 65.8%) compared with non-DRE (all p-values <.001). Among all veterans, the best overall algorithm (area under the curve [AUC] = .701) identified DRE as either (1) exposure to 3+ ASMs or (2) exposure to two ASMs for at least 1 year, with the requirement of past EEG/MRI and intractable ICD code documentation. This algorithm was also highly effective among veterans who received CEC (AUC = .756) or only non-CEC care (AUC = .678). SIGNIFICANCE: This national validation study confirms that medication-based algorithms can identify DRE within VHA administrative data across care settings (CECs and non-CECs). This supports the implementation of a standardized DRE definition for quality improvement, surveillance, and referral optimization within the VHA.

Epilepsia
Michael E. DeBakey VA Medical Center (US), San Francisco VA Medical Center (US), Harvard University (US), University of Miami (US), Oregon Health & Science University (US), University of California, San Francisco (US), Baylor College of Medicine (US), Virginia Commonwealth University (US), University of Utah (US), University of Michigan (US), University of Florida Health (US), VA Boston Healthcare System (US), Hunter Holmes McGuire VA Medical Center (US), Audie L. Murphy Memorial VA Hospital (US), Portland VA Medical Center (US), Murphy Oil Corporation (United States) (US), University of Alabama at Birmingham (US), Yale University (US), University of Florida (US), VA Connecticut Healthcare System (US), James A. Haley Veterans' Hospital (US), VA Salt Lake City Healthcare System (US), Oklahoma City VA Medical Center (US), Malcom Randall VA Medical Center (US), Bruce W. Carter VA Medical Center (US), Michigan Medicine (US), Birmingham VA Medical Center (US), Jesse Brown VA Medical Center (US), Durham VA Medical Center (US), Baltimore VA Medical Center (US), Minneapolis VA Medical Center (US), UAB Medicine (US), University of Oklahoma Health Sciences Center (US), University of Colorado Anschutz Medical Campus (US), Virginia Commonwealth University Medical Center (US)
U.S. Department of Defense, SK Life Science, Congressionally Directed Medical Research Programs, U.S. Army Medical Research Acquisition Activity
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon